CAESAREA, Israel, July 6, 2026
IceCure Medical Ltd. has announced accelerating commercial adoption of its ProSense™ cryoablation system in Brazil following the U.S. Food and Drug Administration (FDA) marketing authorization for the treatment of early-stage, low-risk breast cancer. The company reported growing physician interest and increased commercial procedures across Brazil’s expanding interventional oncology market, supported by the device’s existing ANVISA regulatory approval and rising awareness generated by the recent FDA milestone. The minimally invasive ProSense™ liquid nitrogen-based cryoablation technology is increasingly being adopted as a safe and effective alternative to conventional surgery for the treatment of breast, kidney, lung, bone, and musculoskeletal tumors. IceCure also highlighted significant progress in ongoing independent clinical research and physician education initiatives, reinforcing the company’s strategy to expand global access to advanced tumor cryoablation technology while improving patient outcomes through minimally invasive cancer treatment.
FDA Authorization Accelerates Global Adoption of ProSense™ Cryoablation
The recent FDA marketing authorization for ProSense™ in selected patients with early-stage, low-risk breast cancer has significantly increased international awareness of the technology, particularly in Brazil’s rapidly growing interventional oncology sector. According to IceCure, physicians and healthcare institutions are showing greater interest in incorporating cryoablation into routine clinical practice due to its ability to destroy tumors through controlled freezing while preserving healthy surrounding tissue. Unlike conventional surgery, ProSense™ offers patients a minimally invasive outpatient procedure, shorter recovery periods, reduced procedural trauma, and improved quality of life.
The technology is already being used commercially in Brazil following ANVISA approval, with physicians performing procedures for breast, lung, kidney, and musculoskeletal tumors. Company leadership believes the combination of U.S. regulatory validation and expanding international clinical experience is accelerating physician confidence and supporting broader commercial adoption across major oncology centers worldwide.
Large International Clinical Studies Strengthen Evidence for Breast Cancer Treatment
Advertisement
IceCure also highlighted major independent clinical studies designed to further validate the effectiveness of ProSense™ cryoablation in breast cancer. In Brazil, renowned breast surgeon Dr. Vanessa Sanvido is leading the ongoing SIX Trial, which aims to enroll approximately 750 patients evaluating breast cancer cryoablation using ProSense™. Meanwhile, in France, Dr. Toulsie Ramtohul of the Institut Curie is preparing to lead the large-scale CRYODESC Trial, an independent 900-patient study comparing cryoablation with current standards of care.
During SOBRICE Onco 2026, one of Brazil’s premier interventional oncology congresses, both physicians shared their clinical experience and emerging evidence with Brazilian healthcare professionals. Dr. Ramtohul additionally conducted educational masterclasses at Albert Einstein Hospital in São Paulo, supporting physician training and expanding awareness of minimally invasive breast cancer treatment. These large investigator-led studies are expected to generate valuable real-world clinical evidence supporting the broader integration of cryoablation into international breast cancer treatment guidelines.
Minimally Invasive Oncology Technology Expands Global Cancer Care
The continued expansion of ProSense™ demonstrates the growing role of image-guided cryoablation technologies in modern cancer treatment. IceCure’s proprietary liquid nitrogen-based cryoablation platform enables physicians to precisely destroy tumors through controlled freezing without requiring extensive surgery, making it an attractive option for carefully selected patients seeking less invasive treatment alternatives. Beyond breast cancer, the technology continues to gain adoption across kidney, lung, bone, and musculoskeletal oncology applications, reflecting its versatility across multiple tumor types.
IceCure remains focused on supporting worldwide commercialization through ongoing physician education, regulatory achievements, strategic partnerships, and robust clinical research programs. As healthcare systems increasingly prioritize minimally invasive interventions that improve patient recovery while maintaining therapeutic effectiveness, ProSense™ is well positioned to become an increasingly important tool within the evolving field of interventional oncology, supporting precision cancer care through innovative medical technology.
Source: IceCure Medical press release
